IRVING, Texas--(BUSINESS WIRE)--biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization ...

Represents an inventory impairment charge of $1.3 million related to the January 2026 voluntary recall of select lots of bioidentical hormone pellets shipped by Asteria Health between May 2025 and ...

biote Corp. returned to profitability in Q3 2023 and is expected to continue to be profitable in the future. The company's growth is driven by the sale of hormone replacement therapy products and its ...

Image source: The Motley Fool. biote (NASDAQ:BTMD) reported lower total and procedure revenues, attributed to elevated clinic attrition and a voluntary product recall, but offset these pressures with ...

COLUMBUS, GA, UNITED STATES, March 3, 2026 /EINPresswire.com/ — OBGYN Specialists of Columbus is helping women better understand Bioidentical Hormone Replacement ...

We recently published a list of 10 Micro-Cap Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where biote Corp. (NASDAQ:BTMD) stands against other micro-cap ...

IRVING, Texas--(BUSINESS WIRE)-- Biote (BTMD) (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, ...

IRVING, Texas, March 11, 2026--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced ...

These may include BioTE bioidentical hormone pellets, transdermal formulations, or injections. For patients choosing BioTE, an in-office pellet insertion is scheduled with clear expectations regarding ...

biote Corp. (NASDAQ:BTMD) Q4 2025 Earnings Call Transcript March 11, 2026 biote Corp. beats earnings expectations. Reported EPS is $0.06339, expectations were $0.04. Operator: Good day, and welcome to ...